Mizuho Securities analyst Irina Koffler raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $46.00 (from $43.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Centers for Medicare and Medicaid Services and American Dental Association Establish New Reimbursement for EXPARELNovember 2, 2018 2:13 PM Centers for Medicare and Medicaid Services and American Dental Association Establish New Reimbursement for EXPARELNovember 2, 2018 2:12 PM Increasing unusual option volume: VIXY PCRXNovember 2, 2018 9:40 AM Pacira Pharmaceuticals (PCRX) PT Raised to $47 at BMO CapitalNovember 2, 2018 8:13 AM Pacira Pharmaceuticals (PCRX) PT Raised to $60 at RBC CapitalNovember 2, 2018 7:14 AM Pacira Pharmaceuticals (PCRX) PT Raised to $63 at JMP SecuritiesNovember 1, 2018 4:12 PM Pacira Pharmaceuticals (PCRX) PT Raised to $60 at Needham & CompanyNovember 1, 2018 3:49 PM Pacira Pharmaceuticals (PCRX) PT Raised to $55 at Piper JaffrayNovember 1, 2018 1:13 PM UPDATE: Pacira Pharma (PCRX) Tops Q3 EPS by 23c, Revenues Beat; Boosts FY18 Revenue OutlookNovember 1, 2018 8:13 AM Pacira Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial ResultsNovember 1, 2018 8:00 AM Pacira Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial ResultsNovember 1, 2018 8:00 AM